BCR and mantle cell lymphoma: While some MCL cell lines are highly sensitive to the B cell receptor (BCR) signaling inhibitors ibrutinib and sotrastaurin, other MCL cell lines, including Z-138 and Maver-1, are insensitive and demonstrate activation of the non-canonical NF-κB pathway, instead of the canonical pathway [1].